- Rethymic — Enzyvant Therapeutics’ drug is designed to treat children with congenital athymia, a rare immune disorder in which a child is born without a thymus, an organ that plays a critical role in helping the body learn to fight infections.
- Byooviz — The first biosimilar biosimilar drug to Roche’s Lucentis treats several eye diseases. Byooviz is made by Samsung Bioepis.
- Vivistim Paired VNS System — A device, made by MicroTransponder, is intended to treat moderate to severe upper extremity motor deficits caused by a stroke.
- Comirnaty — Pfizer’s COVID-19 vaccine, the first to receive full approval from the FDA. Moderna and Johnson & Johnson’s COVID-19 vaccines haven’t received full approval and are available under emergency use authorizations.
- Xywav — Jazz Pharmaceuticals’ drug is used to treat a rare sleep condition.
- Nexviazyme — Genzyme’s drug is used to treat Pompe disease, a rare genetic disease that causes muscle weakness and premature death from respiratory or heart failure.
- Semglee — Made by Mylan, it’s the first interchangeable biosimilar insulin product approved in the U.S.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
